Product image of Meliglix 50 Mg (Sitagliptin) supplied by GNH India

Meliglix 50 Mg

Active Ingredient:
Sitagliptin
Origin:
EU

Meliglix 50 Mg (Sitagliptin)

Sitagliptin, the active ingredient in Meliglix 50 Mg, is a DPP‑4 inhibitor presented as a 50 mg tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used with diet and exercise.

GNH India supplies Meliglix 50 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products sourced from the European Union market. The company ensures quality assurance through rigorous testing and regulatory compliance.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is used in the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.

  • Type 2 diabetes mellitus (monotherapy): reduces fasting and post‑prandial glucose levels.
  • Type 2 diabetes mellitus (combined with metformin): provides additional HbA1c reduction.
  • Type 2 diabetes mellitus (combined with other antidiabetics): supports overall glycemic management.

How It Works

  • Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, sitagliptin increases circulating incretin levels, enhancing glucose‑dependent insulin secretion, suppressing glucagon release, and ultimately improving post‑prandial and fasting glucose control without causing hypoglycaemia when used alone.

Side Effects

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection symptoms.
  • Headache: transient mild to moderate pain.
  • Upper respiratory tract infection: cough, sore throat, or congestion.
  • Urinary tract infection: dysuria, frequency, or urgency.
  • Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain possibly radiating to the back.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Severe joint pain: unexplained arthralgia requiring medical evaluation.
  • Bullous pemphigoid: blistering skin disorder.
  • Hepatic failure: signs of liver dysfunction such as jaundice.

Precautions & Warnings

When prescribing sitagliptin, clinicians should consider several safety aspects.

  • Renal impairment: dose adjustment may be required based on estimated glomerular filtration rate.
  • Hepatic impairment: use with caution; monitor liver function tests.
  • History of pancreatitis: avoid use or discontinue if symptoms recur.
  • Concomitant insulin or sulfonylureas: monitor for hypoglycaemia and adjust doses accordingly.
  • Pregnancy and breastfeeding: safety not established; discuss risks with a healthcare professional.
  • Store at ambient temperature: keep in the original pack, protect from moisture and light.

Avoid Interactions

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise plasma concentrations.
  • Insulin or sulfonylureas: increased risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may reduce glucose‑lowering effect.
  • Rifampin: may decrease sitagliptin plasma levels.
  • ACE inhibitors: monitor renal function and electrolytes.

Frequently Asked Questions

Meliglix 50 Mg contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve glycaemic control when combined with diet and exercise, either as a stand‑alone therapy or in combination with other antidiabetic agents such as metformin.

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of the incretin hormones GLP‑1 and GIP, leading to increased insulin secretion and reduced glucagon release in a glucose‑dependent manner, thereby lowering blood glucose levels.

The appropriate dose of Meliglix 50 Mg is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

The safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Meliglix 50 Mg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meliglix (sitagliptin) belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin release with a low risk of hypoglycaemia compared with sulfonylureas. Unlike metformin, it does not affect gastrointestinal absorption, and it can be combined with many other agents, providing flexibility in treatment regimens.

Store Meliglix 50 Mg tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid exposure to extreme temperatures or humidity.

Meliglix 50 Mg is taken orally as a tablet. Swallow the tablet whole with a glass of water, preferably once daily, and follow the dosing schedule prescribed by the healthcare professional.

Serious adverse events linked to sitagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Meliglix 50 Mg should be avoided in individuals with a known hypersensitivity to sitagliptin or any excipients in the tablet. It is also contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose‑adjusted, and in those with a history of pancreatitis.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 9 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT